Zoetis is not a broken animal-health franchise; it is a high-quality business being priced as though one end market determines the whole story. The U.S. companion-animal slowdown is real, but the 5.97% selloff has pushed ZTS to $75.34 after a 40.2% YTD decline. Livestock and international growth supply the clearest evidence that this is a concentrated demand problem rather than a global collapse. The bull case is no longer about paying any price for premium growth; it is about buying durable profitability after expectations have been cut.
Management has already put a number on the reset. After Q1 revenue of $2.3 billion grew 3% on a reported basis but was flat organically, Zoetis lowered full-year 2026 adjusted EPS guidance to $6.85-$7.00 from $7.00-$7.10. That cut validates the concern around price-sensitive pet owners and fewer veterinary visits. It also makes the current valuation more useful: the stock is being judged against a reduced earnings bar, not an untouched premium-growth narrative.
Livestock is the clearest counterweight to the U.S. pet weakness. Zoetis reported livestock sales growth of 19% on a reported basis and 14% organically in Q1, with strength across cattle, swine, poultry, and fish. This is not a minor side business masking deterioration everywhere else; it is a growing part of the portfolio that demonstrates the company can still capture healthy demand outside the pressured companion-animal channel.
The geographic split points in the same direction. International sales rose 10% organically, while companion-animal revenue grew only 2% to $1.60 billion. That contrast matters because it narrows the problem to U.S. pet affordability, veterinary traffic, and competitive pressure rather than exposing a broad failure in Zoetis’ global animal-health model. A business with solid international and livestock growth can absorb a rough patch in one market better than the stock’s collapse implies.
The underlying economics still justify a bullish re-rating if demand stabilizes. Zoetis carries a 37.0% operating margin, a 27.5% net margin, and 10.2% EPS growth. The TickerSpark Score stands at 69, supported by a 100 Profitability component, a 73 Valuation component, and an 84 Financial Health component; only the 30 Momentum component clearly argues against the stock today. At 12.39x trailing earnings, ZTS also trades below the 17.47x P/E of REGN and the 41.25x P/E of IDXX, while its earnings record shows seven beats in the last eight reported quarters, including Q2 EPS of $1.87 versus a $1.84 consensus estimate.
That resilience does not erase the possibility that the pet problem becomes structural. Management has cut 2026 guidance twice, warned that U.S. companion-animal demand remains under pressure, and pointed to intensifying competition in major drug categories. Revenue growth is only 2.3%, the Growth component of the TickerSpark Score is 60, and softer demand for premium products could permanently weaken pricing power in Zoetis’ most valuable segment. On that reading, a 12.39x P/E is not a bargain; it is the market’s warning that the old growth trajectory is gone.
The chart reinforces that warning. ZTS remains below its 50-day moving average of $76.60 and far below its 200-day average of $108.05, while the stock has underperformed healthcare by 48.2 percentage points YTD. Analyst consensus is Hold, with 13 Buy ratings and 17 Hold ratings, and there have been zero recent insider buy transactions. The market is not yet confirming a recovery. Still, the latest Q2 earnings beat and the strong non-U.S. and livestock results keep the bearish interpretation from owning the entire story; the evidence supports a damaged growth profile, not a broken franchise.
That is exactly why this is a re-entry setup for long-term bulls rather than a momentum trade. We would build exposure gradually near the current $75.34 level, respect the 52-week low of $71.45 as the key downside line, and demand evidence that U.S. veterinary visits and premium-product demand are stabilizing. A sustained move above the 50-day average at $76.60 would provide the first technical confirmation that the reset is finding buyers, but the investment case does not require a full chart reversal yet.
The trigger that changes our mind is another guidance cut tied to worsening U.S. companion-animal demand. Until that happens, the combination of a 12.39x P/E, 37.0% operating margin, livestock growth, and a recent quarterly EPS beat makes the selloff look excessive. Zoetis deserves a smaller position than it did before the reset, but it does not deserve to be treated like a broken healthcare business.
